GI board review podcast episodes

This episode reduces the entire dysphagia workup to two bedside questions, where food sticks and what sticks when, and shows why each answer selects its own test. It sorts oropharyngeal from esophageal dysphagia, maps the solids-versus-mixed and tempo patterns onto specific diagnoses, and clarifies why new dysphagia is itself an alarm symptom that mandates a scope regardless of age.

Episode two of the Esophageal Symptoms chapter covers the complaints that aren't classic dysphagia: globus, rumination, supragastric belching, functional chest pain, and painful swallowing. The unifying tell is a reflux-looking patient who fails real acid suppression, which means the problem was never acid. Diagnosis is made from the history and exposures; the test only confirms it.

The dysphagias the standard scope-then-manometry workup misses: those after fundoplication and bariatric surgery, and those reaching the esophagus from systemic disease. The unifying skill is knowing which history question surfaces the surgical or systemic story the scope report cannot carry.

Manometry from first principles: every swallow the esophagus has two jobs, the sphincter must open and the body must squeeze in a top-to-bottom wave, and every number the test reports measures one of those two jobs. This episode teaches the order you read them in, sphincter first then body, because that sequence decides which half of the differential you are even in. Master the three numbers here and every motility diagnosis in the chapter becomes a specific pairing of two answers.

Achalasia is where the manometry numbers point most often, and every strange feature of the disease falls out of one lesion: loss of the inhibitory nerves that relax the sphincter and time the wave. The sphincter clamps but never releases, the body loses its wave, and what the body does on those failed swallows names the subtype. Subtype picks treatment because it changes what the procedure has to accomplish.

Once achalasia is off the table, a normal IRP sends you into the body of the esophagus, which can only fail two ways: too much or too little. This episode is the too-much side: distal esophageal spasm and hypercontractile jackhammer. Both hinge on a normal IRP, both require symptoms to count, and both must clear secondary causes before earning the word diagnosis.

The fourth and final Esophageal Motility episode covers the weak-body disorders on a normal IRP: ineffective motility, absent contractility, and scleroderma, then the one diagnosis you are required to distrust, outflow obstruction with an elevated IRP but peristalsis still firing. The weak-body tracings resolve into three different diseases depending on two numbers: what the body is doing and what the LES is doing. Obstruction is never a manometry diagnosis alone; it needs pattern, symptoms, and a confirmatory test.

GERD is a failure of the antireflux barrier, not acid overproduction. Most patients have a normal resting sphincter, so transient lower esophageal sphincter relaxations are the dominant mechanism, and a sliding hiatal hernia amplifies every failure mode at once. Endoscopy grades the erosive damage, sizes the hernia, and decides treatment intensity, surveillance, and surgical candidacy from one look.

Acid-suppressing drugs work only when their mechanism and timing line up. This episode explains why proton pump inhibitors heal erosive disease when histamine blockers fade, why wrong meal timing is the top cause of apparent PPI failure, and where vonoprazan changes the game.

Drug failure on twice-daily acid suppression is not refractory reflux, it is a reason to work the patient up, and the workup usually turns up something other than reflux. The Lyon Consensus framework, with its acid-exposure cutoffs and symptom-association tests, sorts persistent symptoms into confirmed reflux, borderline, reflux hypersensitivity, and functional heartburn. Antireflux surgery is matched to proven reflux and to motility, and it is reserved for the small group left standing after the mimics are excluded.

Episode one of the Barrett Esophagus and Esophageal Cancer chapter covers how to diagnose Barrett's, why the metaplasia climbs toward cancer, and how the dysplasia grade sets the surveillance interval. The organizing idea: the worse the cells look, the faster they progress, and that speed dictates how often you scope. American definition, sampling protocol, screening criteria, and grade-based intervals throughout.

Endoscopic eradication of Barrett esophagus rests on one principle: the segment holds two kinds of tissue that demand two treatments in a fixed order. Resect visible disease first for a staging specimen, then ablate the flat metaplastic field. This episode covers EMR versus ESD, radiofrequency ablation, cryotherapy salvage, and the intensive post-eradication surveillance that recurrence at the junction and buried glands demands.

Esophageal cancer from histology through staging to treatment, built around the one depth boundary that decides endoscopic versus surgical care. Covers adenocarcinoma versus squamous cell, T-stage depth categories, the mucosa-to-submucosa node-risk jump, the fixed staging workup, and the regimens for locally advanced and metastatic disease.

Eosinophilic esophagitis explained from a single mechanism: IL-4 and IL-13 drive eotaxin, eosinophils flood the lining, and chronic inflammation lays down scar. This episode walks the diagnostic criteria, the inflammatory-versus-fibrotic endoscopy split, and the three drugs plus diet, then closes on refractory disease and the dupilumab-plus-dilation combined approach.

Episode two of two on eosinophilic and infectious esophagitis, covering the infections and direct chemical injuries of the esophagus. One principle links them all: the lining got hurt by something that touched it, and immune status, ulcer shape, and biopsy site tell you the agent. Candida, herpes, CMV, pill esophagitis, and caustic ingestion, each read from contact time, anatomy, and host defenses.

H. pylori from biology through eradication and salvage, driven by a handful of load-bearing mechanisms. Urease survival explains both diagnosis and why acid suppression causes false negatives, infection location decides gastric versus duodenal disease, and rising clarithromycin resistance has reshaped first-line therapy toward optimized bismuth quadruple and vonoprazan-based regimens.

Episode two of the Peptic Ulcer Disease and H. pylori chapter covers the ulcers that are not driven by H. pylori. It works through NSAID and aspirin injury and its prevention, the sequential exclusion behind refractory and idiopathic ulcers, and the perforation and penetration emergencies that split on whether the leak is free or contained.

Covers the chronic gastritides and precursor lesions of the stomach for boards, unified by what each disease does to gastrin. Teaches autoimmune atrophic gastritis, the H. pylori Correa cascade toward intestinal-type cancer, Menetrier disease, and Zollinger-Ellison syndrome. Emphasizes the two high-yield differentials: high gastrin sorted by gastric pH, and giant gastric folds sorted by acid output and biopsy.

Episode two of the Gastritis and Gastric Cancers chapter works through the four gastric tumor families where histology and molecular driver are the discriminator: adenocarcinoma by Lauren type, MALT versus large B-cell lymphoma, the three gastric neuroendocrine tumors, and GIST as the model targeted-therapy cancer. Each tumor's biology drives its staging and its drug. Board-relevant triggers, molecular markers, and treatment sequences throughout.

Nonvariceal upper GI bleeding worked as a fixed sequence: perfusion first, diagnosis second, endoscopy third. The first hour moves mortality more than the scope does. Covers resuscitation, transfusion thresholds, pre-endoscopy pharmacology, risk scores, anticoagulant reversal, Forrest-directed endoscopic therapy, and post-hemostasis medical management.

Episode two of the Upper GI Bleeding chapter covers acute variceal hemorrhage and the unusual non-variceal causes a routine scope misses. It anchors on the variceal bundle delivered before endoscopy, early TIPS for the high-risk cirrhotic, and the Sarin split for gastric varices. The second half is a recognition drill: each rare lesion is easy to treat once its history cue is named.

Gastroparesis is one phenotype with three failure points: the vagus for accommodation and coordination, the interstitial cells of Cajal for rhythm, and smooth muscle for force. Diabetes hits two of the three, surgery hits the vagus, idiopathic disease hits the pacemaker, and drugs mimic the whole picture by slowing the antrum. Four-hour scintigraphy with strict drug holds and controlled glucose anchors the diagnosis, and the favored move is often to stop a drug rather than confirm a disease.

Episode two of the Gastric and Small Bowel Motility chapter covers the episodic and functional presentations where the structural workup comes back clean and the pattern carries the diagnosis: cyclic vomiting syndrome, cannabinoid hyperemesis, chronic intestinal pseudo-obstruction, and functional dyspepsia. Reading dilated bowel or delayed emptying as mechanical disease misleads you every time. Each condition is answered by naming the pattern, not by another motility drug.

Celiac disease built from mechanism through monitoring: modified gluten peptides bind HLA-DQ2/DQ8, drive T-cell inflammation, and trigger lymphocyte-mediated villous atrophy. The modern adult presents like IBS, iron deficiency, or an extraintestinal finding, so the threshold to test is broad. Diagnosis is serology-anchored and biopsy-confirmed while the patient still eats gluten, treated by a strict lifelong gluten-free diet with structured monitoring.

Most celiac patients failing a gluten-free diet are not refractory; they are eating hidden gluten or have a coexisting condition, so a structured non-responsive differential precedes any refractory workup. When refractory disease is genuine, the type one versus type two split on intraepithelial lymphocyte phenotype separates a steroid-responsive disease with good survival from a pre-lymphoma syndrome. The malignancy spectrum, enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and small-bowel adenocarcinoma, is the payoff of getting that distinction right.

What to think about when a small-bowel biopsy shows enteropathy and celiac has already been excluded on a gluten-containing diet. Walks the non-celiac differential mechanistically: wheat-related symptom syndromes, autoimmune enteropathy, Whipple disease, drug-induced enteropathies, checkpoint inhibitor enteritis, bacterial overgrowth, and tropical sprue. The histology, the medication list, and the exposure history read in parallel resolve the fork.

Chronic diarrhea is too much stool water, and because normal absorptive efficiency runs near ninety-nine percent, small physiologic insults produce large clinical phenotypes. Episode one builds the four-mechanism framework, osmotic, secretory, fatty, and inflammatory, and lets that mechanism drive a staged workup. History, basic labs, stool studies, and endoscopy sort most patients within a few tests toward a targeted second-stage evaluation.

Episode two of the Chronic Diarrhea and Malabsorption chapter works the patient who arrives after a clean standard workup. Three entities account for most of what the first pass missed: bile acid malabsorption, microscopic colitis, and a structured algorithm for obscure chronic diarrhea. Board-tested reasoning on typing, testing, and the trials that are diagnostic and therapeutic in one step.

Episode one of two on Irritable Bowel Syndrome and functional bowel, covering positive diagnosis, Rome IV criteria, and subtyping. It maps the brain-gut model and its five mechanisms onto the drug classes. It closes with the mechanism-targeted pharmacology of constipation-predominant IBS.

Episode two of the IBS and Functional Bowel chapter covers the diarrhea-predominant subtype, the neuromodulators and behavioral therapies that work across subtypes, and the mechanistic workup of bloating. Drug selection is mechanism-matched to the dominant symptom and driver, not subtype-matched in the abstract. Carry mechanism, subtype indication, and contraindication together to pick the right answer.

Episode one of three on inflammatory bowel disease, covering ulcerative colitis from classification through full medical management. Walks the UC-versus-Crohn distinction, the Mayo score driving severity-tiered therapy, the acute severe UC inpatient script with its day-three salvage rule, mesalamine for mild-to-moderate disease, and mechanism-based positioning of biologics and small molecules. Board-focused framework for choosing therapy by matching drug mechanism to patient phenotype.

Episode two of the IBD chapter takes Crohn disease from phenotype through complete medical management. It runs the Montreal classification into risk stratification and the top-down versus step-up decision, then walks Crohn-specific induction, immunomodulators, and biologic positioning. It closes with the phenotype-specific algorithms for perianal disease, strictures, and post-operative recurrence.

The long-arc complications of IBD after induction and maintenance: the ileal pouch and its inflammations, dysplasia surveillance in long-standing colitis, the extraintestinal manifestations, and pregnancy. The unifying board move is that active disease, not active medication, is the threat, so biologics usually continue through delivery. Localization, timing of surveillance, and whether a manifestation tracks bowel activity are what get tested.

Episode one of two on the Colorectal Cancer, Polyps, and Diverticular Disease chapter, tracing the neoplastic pathway from average-risk screening through molecular subtyping to stage-based treatment and polyp surveillance. The organizing thread is mechanism: why screening starts at forty-five, why MLH1 loss reflexes to BRAF, and why histology sets the surveillance interval.

Diverticular disease as its own entity, following a management algorithm that shifted meaningfully in the last decade while the boards catch up. Uncomplicated diverticulitis is now an inflammatory process treated with selective rather than reflex antibiotics, and prophylactic resection by episode count is dead. Complicated disease grades on Hinchey and splits at the four-centimeter abscess threshold.

Episode one of the Pelvic Floor and Anorectal Disorders chapter works through chronic constipation as a symptom-defined syndrome, the empiric laxative sequence that resolves most patients, and the prescription drugs for refractory disease mapped to four molecular targets. The organizing idea: match the drug to the mechanism, and keep opioid-induced constipation separate because the enteric receptor never develops tolerance. Definitions, alarm features, secondary causes, secretagogues, prucalopride, and the peripherally acting opioid antagonists throughout, all framed around the exam stem that names the mechanism.

Episode two covers the constipation phenotypes that need more than pharmacology: defecatory disorders diagnosed on anorectal manometry and balloon expulsion and treated with biofeedback, and slow-transit constipation documented on a marker or capsule study. The organizing discipline is to decide the mechanism before the next drug, because escalating laxatives in unrecognized outlet dysfunction produces overflow and urgency without relief. The central pitfall runs the whole episode: unrecognized outlet dysfunction falsifies the transit study and sends the wrong patient to colectomy, so check the outlet before you cut the colon. Testing thresholds, the two-of-three diagnostic rule, and precise colectomy criteria throughout.

Episode three covers fecal incontinence managed in a fixed sequence and the benign anorectal disorders anchored to the dentate line. Incontinence rarely fails for a single reason, so the workup canvasses the whole continence stack and the treatment runs from optimizing the modifiable factor through loperamide and biofeedback to sacral neuromodulation, which has displaced sphincteroplasty as first-line surgery for refractory disease. The benign disorders follow the anatomy: above the dentate line means painless bleeding, below it means sharp pain, and that landmark predicts management for hemorrhoids, anal fissure, and pruritus ani. Manometry, endoanal ultrasound, the seventy-two-hour rule, and the atypical-fissure workup throughout.

Episode one of the Liver Test Interpretation chapter turns abnormal liver enzymes into a workup by computing the R ratio and committing to a track before ordering another test. The organizing idea: which enzyme dominates and by how many multiples of normal it sits at frames the entire differential, because hepatocellular and cholestatic patterns share almost nothing. The hepatocellular track runs five layers in order (viral, autoimmune, metabolic, ischemic, drug); the cholestatic track branches on a single ultrasound finding, dilated tree or not. Thresholds, magnitude anchors, and reflex panels throughout.

Episode two of the Liver Test Interpretation chapter covers what to do when a single value is up with everything else normal, or when the labs aren't the bottleneck and imaging and fibrosis assessment are. Each case forces the same question in a different form: what's the next reflex test, and does it commit you to an invasive workup or excuse you from it? Isolated bilirubin splits on direct versus indirect, isolated alkaline phosphatase splits on GGT, and the fibrosis workup runs FIB-4 before elastography before biopsy. Thresholds, mimic vignettes, and the percutaneous-versus-transjugular decision throughout.

Episode one of the Viral Hepatitis chapter builds the acute-hepatitis framework and covers the two fecal-oral viruses, hepatitis A and hepatitis E. The organizing idea: acute viral hepatitis looks the same no matter which virus caused it, so you read the virus off the serology, not the symptoms. It walks the four clinical phases, the four-test acute panel with its two named traps, and then hepatitis A as a post-exposure-prophylaxis decision that splits by age and host. Hepatitis E closes it with its two high-yield scenarios: twenty to thirty percent mortality in third-trimester pregnancy and chronic infection in the immunocompromised.

Episode two steps inside hepatitis B, where the serologic panel is not just diagnostic but a phase grid that determines treatment, the pregnancy strategy, the reactivation rule, and the hepatitis D testing decision. It reads two grids: the serologic grid of surface antigen, core antibody, and surface antibody that places the patient, and the phase grid of e-antigen, DNA, and ALT that decides whether to treat. From there it covers the nucleoside analogs, the three-pillar pregnancy bundle, the preemptive reactivation prophylaxis rule under immunosuppression, and hepatitis D with its new entry inhibitor bulevirtide. Every threshold, drug, and cutoff is named as the boards test it.

Episode three covers hepatitis C, now a curable disease, and tests the entire workflow of cure: identify the virus, confirm replication, stage the liver, pick the regimen, document cure, then ask the one remaining cancer question. It runs the reflex antibody-then-RNA diagnosis, the two pangenotypic direct-acting antiviral regimens plus the salvage regimen, and a special-populations set built on a few absolute rules. Decompensated cirrhosis forbids protease inhibitors; advanced kidney disease no longer forbids sofosbuvir. It closes on the highest-yield post-cure point: cancer surveillance continues forever in F4 cirrhosis but stops in F3 fibrosis short of cirrhosis.

Episode one of the Drug-Induced Liver Injury and Acute Liver Failure chapter builds drug injury from a single mechanism: cytochrome oxidation makes a reactive intermediate, phase-two conjugation quenches it or fails, and injury appears where phase one outpaces phase two. That frame makes the offender lists predictable, the histology readable, and the severity rules non-arbitrary. Hy's Law converts biochemistry into a triage decision, R value predicts trajectory, and histology patterns map backward to drug classes. Acetaminophen is the prototype that runs the whole sequence at speed, with the Rumack-Matthew nomogram, N-acetylcysteine, and time-to-treatment mortality all board-tested cold.

Episode two shifts from the drug to the failing organ, asking whether the liver can still recover on its own, how much time you have to decide, and when a different liver is the only answer. It anchors on the four-criterion definition of acute liver failure, then shows how etiology maps directly to the probability of spontaneous recovery. Two special causes, Wilsonian and herpes acute liver failure, each carry a distinctive fingerprint that demands empiric therapy before the workup completes. The King's College Criteria then triage who gets listed, with separate acetaminophen and non-acetaminophen paths calibrated to that recovery probability.

Episode one of the Autoimmune and Cholestatic Liver Diseases chapter builds the sorting framework for the three immune liver diseases and then works autoimmune hepatitis in depth. The organizing idea: pattern plus demographics plus antibodies place a patient into autoimmune hepatitis, primary biliary cholangitis, or primary sclerosing cholangitis within the first two sentences of the vignette. Autoimmune hepatitis is then the ANA and smooth-muscle-antibody interface hepatitis of the middle-aged woman with elevated IgG, confirmed on biopsy. The second half is treatment: steroid induction plus a steroid-sparing agent, the type one versus type two split, the simplified score, and why withdrawal is cautious because relapse is the rule.

Episode two works primary biliary cholangitis, the anti-mitochondrial-antibody cholestatic disease of the middle-aged woman, as a biochemical-target-driven problem. The diagnosis is usually made on labs alone, treatment starts with ursodeoxycholic acid for everyone, and escalation is driven by where the alkaline phosphatase and bilirubin sit at twelve months, because those numbers are the surrogate for survival. The second-line landscape changed when obeticholic acid left the US market, leaving elafibranor and seladelpar as the two approved PPAR-targeted agents that tend to improve rather than worsen the itch. The close is the stepped, mechanism-targeted pruritus algorithm from cholestyramine through rifampin, sertraline, naltrexone, and the emerging ileal transporter inhibitors.

Episode three works primary sclerosing cholangitis, the multifocal stricturing disease of the man with ulcerative colitis, as a recognition-and-surveillance problem, then covers its steroid-responsive mimic. MRCP not serology makes the diagnosis, the alkaline phosphatase is normal in nearly half of patients at any moment, and because there is no proven medical therapy the work is surveillance for three cancers. The chapter closes on IgG4-related sclerosing cholangitis, the older man with painless jaundice and a sausage-shaped pancreas who responds dramatically to corticosteroids and must not go to a Whipple, plus the two overlap syndromes. Cancer thresholds, the dominant stricture workup, and the high-dose ursodeoxycholic acid harm signal run throughout.

Episode one of the Steatotic Liver Disease chapter reframes fatty liver as MASLD, a positive diagnosis built on hepatic steatosis plus at least one of five cardiometabolic criteria rather than an exclusion. The organizing idea: fibrosis stage, not the transaminase or the degree of steatosis, is the prognostic anchor, so the workup runs a tiered noninvasive sequence and management is graded by how much fibrosis is present. It walks the biology of insulin resistance and lipotoxicity, the PNPLA3 and TM6SF2 variants, lean disease and cryptogenic cirrhosis as the same entity, then the FIB-4 into elastography algorithm. Management climbs from weight-loss targets through bariatric surgery, including compensated cirrhosis, to the newly on-label drugs resmetirom and semaglutide.

Episode two moves along the alcohol continuum to alcohol-associated liver disease, one biology read across steatosis, steatohepatitis, and cirrhosis, then zeroes in on the acute superimposed syndrome of severe alcoholic hepatitis. The organizing idea: severe disease is defined by a Maddrey above thirty-two or a MELD over twenty, treated with prednisolone only after infection is excluded, with the day-seven Lille score as the binary decision to continue or stop. It works through the AST-greater-than-ALT lab signature, the ethanol-metabolism mechanism that drives it, and the drug interactions that follow. The close is early transplant for selected steroid nonresponders, which retired the old six-month sobriety rule in favor of a structured psychosocial assessment.

Episode one of the Inherited Liver Diseases chapter takes hereditary hemochromatosis and reasons from the molecular lesion outward: lose the HFE signal, lose the hepcidin brake, and iron pours in unchecked for decades. The organizing move is that genotype alone is a substrate, not a disease, so diagnosis rests on biochemistry plus genotype, not a positive C282Y result by itself. Iron regulation, the C282Y and H63D alleles, incomplete sex-skewed penetrance, the two-tier diagnostic framework, phlebotomy to a ferritin target, and the reversibility line all run through the episode. The recurring trap is the healthy homozygote with normal iron studies who is surveyed, not treated.

Episode two takes the other metal-handling disease, Wilson, where the toxin is copper and the ATP7B pump fails at two coupled jobs: pushing copper into bile and loading it onto ceruloplasmin. The diagnostic logic is harder because no single test stands alone, so the Leipzig score integrates weighted features and the chelator choice turns on the speed and site of copper movement. Low ceruloplasmin, high urinary copper, the fulminant fingerprint, and trientine-plus-zinc therapy run through the episode. The board traps are the young steatohepatitis patient without metabolic syndrome and the misread fulminant case that costs the transplant window.

Episode three closes the chapter with the four inherited liver diseases beyond the metal pair: alpha-one antitrypsin deficiency, cystic-fibrosis-associated liver disease, polycystic liver disease, and the familial cholestatic syndromes. The unifying move is that mechanism predicts therapy in each one, and each carries a distinct board trap. Alpha-one antitrypsin is the two-organ split where augmentation rescues the lung and does nothing for the liver; CF liver disease is one causal chain treated at three points; polycystic liver disease is synthetic-function-preserved mass effect; and the cholestatic syndromes split by the GGT pattern and cancer risk. Ileal bile acid transporter inhibitors, CFTR modulators, and the MELD exception anchor the modern management.

Episode one of the Portal Hypertension and Cirrhosis Complications chapter treats portal hypertension as a pressure problem first, then follows that pressure into varices and bleeding. The organizing idea: the hepatic venous pressure gradient is the hemodynamic gold standard, and liver stiffness plus platelets give the noninvasive translation that now drives beta-blocker and screening decisions. Screening thresholds, primary prophylaxis, and the acute variceal hemorrhage bundle all key off the same physiology, with the restrictive transfusion target, mandatory ceftriaxone, and the early-TIPS decision as the cirrhosis-specific layers. It closes on gastric varices, portal hypertensive gastropathy, and GAVE, where anatomy and drainage pick the therapy, not appearance.

Episode two follows the splanchnic vasodilation cluster, where one upstream physiology produces four complications, each with its own bundle, threshold, and drug sequence. Portal hypertension drives splanchnic vasodilation, the kidney reads effective hypovolemia and retains sodium, and from that single mismatch flow ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic encephalopathy. The episode anchors ascites on the serum-ascites albumin gradient and the fixed spironolactone-to-furosemide ratio, then moves through the TIPS-versus-paracentesis decision, hyponatremia thresholds, the peritonitis antibiotic-plus-albumin bundle, terlipressin for hepatorenal syndrome, and lactulose plus rifaximin for encephalopathy. Every threshold is mechanism-derived rather than arbitrary.

Episode three covers the decompensated complications that do not flow primarily through splanchnic vasodilation, starting with two pulmonary syndromes that look related but are physiologically opposite. Hepatopulmonary syndrome is capillary dilation with shunt physiology, recognized by platypnea and orthodeoxia, while portopulmonary hypertension is arteriolar constriction diagnosed by right heart catheterization, and that single distinction picks the therapy and changes the transplant calculus. The episode then works the coagulopathy where the INR misleads because cirrhotic hemostasis is rebalanced rather than impaired, so paracentesis and thoracentesis need no correction. It closes on the vascular liver diseases sorted by anatomic level, Budd-Chiari, sinusoidal obstruction syndrome, portal vein thrombosis, porto-sinusoidal vascular disease, and shock liver.

Episode one of the Liver Tumors and Transplant chapter runs the benign masses on a single decision: imaging appearance plus hormonal or drug context usually settles the diagnosis, and biopsy enters only when the imaging is atypical or the lesion has real malignant potential. Peripheral nodular enhancement filling inward is a hemangioma, hepatobiliary-phase retention is focal nodular hyperplasia, and hepatobiliary-phase darkening is an adenoma. From the adenoma you stratify by sex, size, growth, and beta-catenin status, because that subtype is what turns a benign mass into a resection case. The two edge entities, nodular regenerative hyperplasia and peliosis hepatis, round out the pattern-recognition set.

Episode two works hepatocellular carcinoma as one continuous algorithm built on a single override: a new lesion in a cirrhotic or chronic hepatitis B liver is HCC until proven otherwise. Surveillance goes to every Child-Pugh A or B cirrhotic and to high-risk hepatitis B, by ultrasound and AFP every six months timed to the tumor doubling time and the curative-size cutoffs. LI-RADS turns that finding into a diagnosis, with the definite category diagnostic by imaging alone and the two special categories forcing biopsy or excluding transplant. The BCLC system then turns the diagnosis into the treatment the physiology will actually permit, from resection and ablation, through transplant within Milan, to locoregional therapy and first-line atezolizumab plus bevacizumab for advanced disease.

Episode three organizes cholangiocarcinoma anatomy first, biology second, because where the tumor sits dictates the operation and the transplant path. Intrahepatic disease is resected when possible and is a transplant contraindication over two centimeters, distal disease gets a Whipple, and perihilar disease is resected when resectable with a narrow unresectable subset going through a neoadjuvant-then-transplant protocol. The imaging is delayed enhancement without washout, the mirror image of HCC, because the fibrous stroma traps contrast rather than letting it run through. CA 19-9 is a trend rather than a yes-or-no and is unusable in Lewis-negative patients, so sclerosing cholangitis patients with a new dominant stricture get FISH on the brushings when cytology fails them.

Episode four follows a patient across the whole transplant arc, organized by two clocks: the allocation score that triages who is sickest, and time itself, which orders both the drop in immunosuppression intensity and the shift from acute risk to cumulative toxicity. The calculated score does the primary triage with its sex and albumin corrections fixing real undervaluation, the workup confirms the operation can succeed medically, infectiously, and psychosocially, and the exception points cover the diseases the labs cannot see. Donor type then sets the complication profile, immunosuppression intensity organizes the early timeline of rejection and opportunistic infection with CMV dominant, and cumulative toxicity organizes the late timeline. The original disease returns in a pattern specific to its cause, which is why surveillance continues indefinitely.

Episode one of the Acute Pancreatitis chapter follows a single mechanism from trypsin escaping its compartment to the cytokine cascade, third-spacing, and lost pancreatic perfusion. The organizing idea: every first-hours decision reaches back to that mechanism. The two-of-three rule diagnoses around the failure modes of pain, enzymes, and imaging alone; the cause is worked up on admission because the trigger reshapes management; severity stays provisional while organ failure declares; and fluids are moderate lactated Ringer's titrated to hematocrit and BUN. The trial that asked whether more fluid was better answered no and stopped early.

Episode two works through three first-days decisions where the intuitive older instinct turns out to be net harmful. Pancreatic rest with TPN increases infection because an empty lumen lets villi atrophy and gut bacteria translocate into necrotic tissue, so early enteral feeding wins. Universal urgent ERCP was wrong because most triggering stones have already passed, leaving an empty duct and only post-ERCP risk. And interval cholecystectomy costs roughly one in six patients a recurrent biliary event, so same-admission surgery is now standard. The unifying logic: each intervention earns its place against its own complication profile.

Episode three picks up where the pancreas has declared itself necrotic and organizes the collection nomenclature on timing and content. Necrosis is managed by delay, drain, then debride, with endoscopic transmural drainage now favored because it never crosses the peritoneum. The vascular complications split by vessel: venous thrombosis usually self-resolves, while a pseudoaneurysm mandates CT angiography and embolization before any drainage. The post-ERCP triad attacks three independent nodes, and recurrent disease is worked up by escalation from baseline labs to MRCP to endoscopic ultrasound for microlithiasis, with the pancreas divisum trap waiting at the end.

Episode one of the Chronic Pancreatitis, Cysts, and Neoplasms chapter builds the framework from a single fact: fewer than three percent of heavy drinkers ever develop the disease, so exposure alone is never enough and a co-modifier has to do the converting. The organizing idea is that tobacco and a genetic background decide who progresses, and where each gene sits in the trypsin-control pathway sets its inheritance, penetrance, and cancer risk. Diagnosis is calibrated to stage, CT for calcification, secretin-MRCP for the duct, endoscopic ultrasound for minimal-change parenchyma, and function testing for the gland that still looks normal. Pain is worked in steps, from cessation and non-opioid analgesics through neuromodulators to decompression, with the randomized shift that moved early surgery ahead of endoscopy the tested pivot. Cause, mechanism, staging, and steps throughout.

Episode two follows three threads that all trace to the same parenchymal loss the framework episode set up. The acini die and enzyme replacement stands in, but only if dosed with the meal and released at the right duodenal pH, so a proton pump inhibitor enters when the coating fails. The islets die and produce a diabetes defined not by insulin lack but by lost glucagon, which makes hypoglycemia the dominant management feature and steers drug choice away from sulfonylureas. The structural disruption produces complications whose management is read directly off the anatomy, drain the symptomatic pseudocyst, recognize disconnected duct as the exception, and take the spleen out when left-sided portal hypertension bleeds. Mechanism first, management second, throughout.

Episode three steps outside the alcohol-and-tobacco gland to a diagnosis that sits at a costly decision point: steroids given to a patient who actually has adenocarcinoma cost the curative resection window. Autoimmune pancreatitis splits on mechanism, type one a systemic IgG4-related plasma-cell disease of older men with painless jaundice, type two a duct-centered process a decade younger tied to inflammatory bowel disease. Demographics, imaging, serology, other-organ involvement, and histology all line up behind that one distinction, and the criteria are structured precisely because the mass mimics cancer. The steroid trial is pulled in as a diagnostic element, but when the differential with adenocarcinoma stays genuinely unresolved, surgery comes first. Mechanism drives the whole call.

Episode four takes the incidental cyst through the same endoscopic-ultrasound-and-fluid pathway used for the autoimmune mass, but the cost runs the other way: resecting a cyst that was never going to become cancer commits a patient to major-operation morbidity for nothing. The organizing question is whether the epithelium is mucinous, because only the mucinous lesions carry progressive dysplasia, and the fluid answers it, CEA and glucose for mucin, amylase for duct communication. Demographics and imaging give a pretest guess, then the biochemistry classifies the lesion cleanly. The intraductal mucinous neoplasm is the one left to surveil, where high-risk stigmata mandate resection, worrisome features trigger endoscopic ultrasound, and a size-stratified MRI schedule runs only while it can still change management. Thresholds are the trap throughout.

Episode five closes the chapter with two tumors that share the same pancreas and almost nothing else. Adenocarcinoma is desmoplastic, poorly enhancing, presents late with painless jaundice, and is staged by its relationship to four vessels into the resectability categories that drive surgery-versus-systemic-therapy. The neuroendocrine tumors are islet-derived, hypervascular, and often announce themselves with a hormone syndrome while still small, sorted by functional pattern and grade. The same core biopsy and multiphase CT serve both, but everything downstream diverges, so the work is holding the two algorithms apart. Biology sets the staging language, and the staging language sets the treatment, from neoadjuvant FOLFIRINOX to somatostatin analogs and radionuclide therapy.

Episode one of the Biliary Tract Disease chapter starts with the stone, because the phenotype tells you what biochemical environment produced it, and that environment is really the risk-factor list seen from the mechanism side. Cholesterol stones come from supersaturation, dysmotility, or nucleation; black pigment stones from excess unconjugated bilirubin; brown pigment stones form new in the duct under stasis plus bacterial deconjugation. Asymptomatic stones are observed because the math favors it, unless a cancer or surgical-emergency configuration shifts the calculus, and true biliary colic tips a fit patient toward cholecystectomy. When persistent obstruction converts colic into acute cholecystitis, the Tokyo grade dictates how aggressively to operate, with the friable ischemic wall of the acalculous and emphysematous variants pushing drainage back toward the percutaneous route.

Episode two covers the less common gallbladder presentations, and the thread running through all of them is the same: chronic inflammatory remodeling around the gallbladder distorts the anatomy enough to change either the operation, the cancer risk, or the diagnostic frame. Stone-driven inflammation at Calot's triangle either compresses the bile duct from outside in Mirizzi, calcifies the wall in porcelain gallbladder, or erodes into bowel in gallstone ileus and Bouveret. The Csendes stage sets the reconstruction, the calcification pattern sets the cancer indication, and the level of stone impaction sets endoscopy versus surgery. Polyps test on a clean size rule with risk-factor modifiers, and functional gallbladder disorder tests on the discipline not to operate, because the failure mode is over-treating a heterogeneous category.

Episode three takes the stone into the bile duct, and the whole problem sits on a probability question, because ERCP carries its own complication profile, headlined by post-ERCP pancreatitis. You earn the right to do an ERCP by raising the pretest probability of a retrievable stone high enough to justify the procedural risk, so high-probability patients go straight to ERCP while intermediate patients confirm the stone first with MRCP or endoscopic ultrasound. When the same stone turns septic, cholangitis runs on a hydraulic mechanism: the obstruction raises intraductal pressure and refluxes bacteria into the blood, which is why antibiotics alone cannot fix it and decompression is mandatory. The Tokyo grade scales the timing, and clinical improvement on antibiotics is never mistaken for a relieved obstruction.

Episode four turns to the duct that is structurally abnormal from birth or made abnormal by an operation, where the recurring move is to read the anatomy and let it dictate whether an endoscopic fix can work at all. Choledochal cysts drive cholangiocarcinoma through decades of epithelial exposure to refluxed enzymes, and the Todani type dictates the operation, with complete excision the rule and the choledochocele the low-risk exception. Bile leak and stricture are the iatrogenic version, where the Strasberg level decides whether endoscopic stenting can bridge the injury at all, so a cystic-stump leak seals with a stent while a complete transection needs hepaticojejunostomy. Sphincter of Oddi dysfunction divides into a true stenosis that sphincterotomy cures, a functional pain that a procedure only harms, and a heterogeneous middle where empiric sphincterotomy beats a manometry-driven workup.

Episode one of the ERCP and EUS Procedures chapter starts from the single fact that reorganizes everything: ERCP is a therapy, not a test, so you earn the right to do it only when a non-invasive study cannot answer the question. From there the whole episode is risk management. Wire-guided cannulation replaces the hydraulic contrast push that floods the pancreatic duct, difficult-cannulation maneuvers each solve one anatomic problem, and the prophylaxis stack is held by mechanism because the mechanisms tell you who needs which. The organizing thread: find the duct by guidance, then stack indomethacin, a pancreatic duct stent, and lactated Ringer on the patient whose risk factors say the pancreas will react.

Episode two is about the decision that comes before cannulation and the restraint it takes to decline the procedure when objective evidence for benefit is absent. A landmark sham-controlled trial retired type three sphincter of Oddi dysfunction as a sphincterotomy indication, so pain with normal labs and a normal duct becomes a functional pain disorder, not an ERCP. Pregnancy raises the threshold highest because a second patient absorbs all the risk and none of the benefit. The back half turns on two failure mechanisms, the cut that bleeds and the elevator that harbors biofilm, and each names the patient to protect and the device choice that protects them.

Episode three centers on the stricture you cannot name: painless jaundice, a tight narrowing, and imaging that says cancer without proving it. Tissue acquisition is the whole game, and every step up the diagnostic cascade works by getting closer to the tumor, from a shallow brush that misses submucosal cholangiocarcinoma to intraductal biopsy and FISH to cholangioscopy to an EUS needle in the mass itself. The transplant candidate inverts that hierarchy, because a needle in the hilar primary can seed the peritoneum and disqualify the cure. Then durable drainage follows anatomy: covered metal distally to block ingrowth, uncovered metal at the hilum to preserve side branches, and always enough viable liver drained to clear the bilirubin.

Episode four picks up the moment standard ERCP fails, and it runs on a single habit: name the anatomic barrier and let it choose the technique. When you cannot cannulate the papilla, a dilated duct becomes an EUS target, and the finishing options rank by how much natural drainage they keep, rendezvous over choledochoduodenostomy over hepaticogastrostomy. When surgery has hidden the papilla, the question is how to restore the duodenoscope's en face view through the particular barrier, so EDGE tunnels into the bypassed stomach, balloon enteroscopy reaches a hepaticojejunostomy, and a reversed cautious approach handles Billroth two. Device design and technique are consequences of the anatomy, not lists to memorize.

Episode five holds EUS and ERCP to one standard in the pancreatitis spectrum: they earn their place only when there is structural disease or stone burden to act on, because every procedure carries a real pancreatitis risk weighed against a modest expected benefit. In the recurrent-attack workup, EUS for microlithiasis is the highest-yield study after MRCP, while sphincterotomy for divisum and idiopathic disease is the reflex sham-controlled data have humbled. In the chronic gland you decompress discrete obstructive lesions and read the true predictors of success, disease duration, cessation, and stone burden rather than head calcification. Standing over all of it, a randomized trial favors early surgical drainage for the painful dilated duct.

Episode six takes the pancreatitis spectrum to its end: the collections the gland leaves behind. Timing runs on wall-maturation logic, waiting about four weeks for a rind strong enough to hold a transmural anastomosis, and the contents decide everything downstream, since a pseudocyst and walled-off necrosis need different stents and different follow-through. Before any puncture you image for a pseudoaneurysm and embolize it first, because needling a shared wall can cause uncontrolled hemorrhage. Drainage is a step-up, transmural first and necrosectomy only when the cavity will not empty, and two failure modes both turn on sequence. Necrosectomy itself carries one non-negotiable safety rule: carbon dioxide insufflation, because air can embolize.

The final episode turns EUS from a guide for therapy into a diagnostician and a palliator, and it runs on one habit: reason from substrate to answer. The five alternating wall layers plus echotexture place a subepithelial lesion and narrow the differential before a needle moves, so a hypoechoic layer-four mass is a GIST until tissue proves otherwise. The needle choice then turns on a single distinction, cells versus architecture, because lymphoma, GIST, and autoimmune pancreatitis all live in structure a core preserves and cytology destroys. Finally the same probe that finds the tumor treats its pain: alcohol neurolysis for cancer, a reversible steroid block for benign disease, with complications that read straight off the interrupted sympathetic outflow.

Episode one of the Endoscopy Practice and Sedation chapter frames the morning of the procedure around two preventable disasters: aspiration and thromboembolism. The organizing idea is that fasting intervals are gastric-emptying kinetics on a clock, and every anticoagulant decision sits at the intersection of procedure bleeding risk and patient thromboembolic risk. That grid tells you who holds, who continues, and who bridges. A single asymmetry runs the antiplatelet decisions: an unrecognized stent thrombosis dwarfs endoscopically manageable bleeding, which is why aspirin usually stays on. Reversal closes the loop, each agent matched to its target.

Episode two frames procedural sedation around one trade: the depth you want versus the depth your team can rescue from. The ASA continuum sets the rescue rule, the practitioner must be able to manage a patient one level deeper than intended, and ASA physical status predicts who tolerates endoscopist-supervised moderate sedation versus who needs anesthesia. Midazolam and fentanyl carry the easy case at the cost of multiplicative respiratory depression; propofol buys fast onset and offset for the complex case at the cost of no antagonist. The alternative agents each solve one problem the standard pair cannot.

Episode three covers the monitoring, prediction, and rescue that catch the patient when the drug carries them past the intended depth. Capnography detects apnea within one to two breaths while pulse oximetry lags on supplemental oxygen, so a flat waveform with a reassuring saturation is apnea. Mallampati and the airway predictors decide whether the standard plan is safe before the first dose, and flumazenil and naloxone reverse the agents but wear off faster than what they reverse. The special populations are not exceptions, they are the same framework run through a shifted pharmacokinetic and aspiration-risk profile.

Episode four closes the chapter on four topics that each test one recognition: when the reflexive answer is wrong because the underlying principle has shifted. Antibiotic prophylaxis turns on closed-space infection, not the prosthetic device, so the 2007 AHA guideline took GI endoscopy off the endocarditis list. Cardiac device management turns on electromagnetic interference, so modern pacemakers tolerate routine polypectomy without reprogramming while ICDs need arrhythmia detection suspended. Capsule endoscopy lives or dies on retention risk addressed by the patency capsule, and the ASGE Cotton lexicon grades adverse events by intensity of intervention.

Episode one of the Colonoscopy Practice and Quality chapter treats screening colonoscopy as a chain of dependencies where the weakest link governs the outcome. The organizing idea: colorectal cancer has a long precursor and a survivable early stage, so everything from the starting age to the withdrawal time exists to make prevention real rather than nominal. It walks the modality menu with the rule that any positive non-invasive test commits the patient to colonoscopy, then the split-dose preparation physiology that delivers a clean right colon. It closes on the detection metrics, adenoma detection rate as the single most validated quality measure and sessile serrated lesion detection rate as its complement on the serrated pathway.

Episode two frames polyp management as a reading task that begins before the snare opens: has the lesion grown horizontally along the mucosa or vertically into the submucosa, because vertical growth is what carries cancer risk. Paris morphology, the NICE and JNET optical patterns, Kudo pit pattern, and the lateral spreading granularity types are all ways of reading that same growth signal, and depressed or pseudodepressed surfaces are what deep submucosal invasion looks like from above. The optical read then dictates the resection plan. Cold snare wins on safety for diminutive and small lesions, hot snare is reserved for the vascularized pedunculated stalk, EMR is standard for larger sessile and lateral spreading lesions, and en bloc resection by ESD or band-ligation is reserved for when specimen integrity is needed for staging.

Episode three resolves the malignant polyp on one anatomic fact: lymphatics in the colon begin at the muscularis mucosae, so disease confined above it cannot metastasize while submucosal invasion opens the door to nodal spread. Intramucosal adenocarcinoma behaves as high-grade dysplasia and is cured by complete resection, which is why the word on the path report pulls toward unnecessary surgery. The Kikuchi and Haggitt systems describe depth, but the modern algorithm aggregates depth with tumor budding, differentiation, lymphovascular invasion, and margin status rather than acting on depth alone. Surveillance then calibrates the next exam to the worst lesion found, with the shortest interval winning when findings conflict and a separate six-month site check for piecemeal EMR of lesions twenty millimeters or larger.

Episode four teaches the post-polypectomy adverse event set through mechanism, because each event has a distinct anatomic or thermal correlate that determines the next move. Immediate bleeding is treated at the visible vessel while delayed bleeding returns for endoscopic hemostasis on the still-recognizable scar, and the prophylactic-clip decision turns on proximal location and antithrombotic risk rather than reflex. Perforation forces a closure decision driven by defect age and size, while post-polypectomy electrocoagulation syndrome mimics perforation but lacks free air and resolves on bowel rest. The unifying frame is that the recognition cue tells you the mechanism and the mechanism tells you the response, so hematochezia, free air, focal peritonitis without free air, and left shoulder pain are not interchangeable.

Episode five closes the chapter on the other half of why colonoscopy quality matters, the serrated pathway where missed right-sided lesions become interval cancer. Sessile serrated lesions run through BRAF V600E, CIMP-high hypermethylation, MLH1 silencing, and microsatellite instability, which is why sessile serrated lesion detection rate is its own quality metric. That molecular route drives the Lynch reflex tree: mismatch repair immunohistochemistry, then BRAF and MLH1 methylation to triage sporadic disease, with the other loss patterns going straight to germline testing because sporadic biology cannot explain them. The special populations then bend the standard algorithm one mechanism at a time, as the kidneys forbid phosphate, the liver forbids morphine, the fetus forbids first-trimester benzodiazepines, and the IBD colon demands chromoendoscopy.

Episode one of the GI Emergencies chapter treats massive upper GI bleeding as a resuscitation problem before it is an endoscopic one. The organizing idea is a clock that starts when the patient arrives, where permissive hypotension protects the clot and the wrong decision made confidently is worse than none. It moves through the timeline the patient is actually on: restrictive transfusion, the balanced massive transfusion ratio and the calcium citrate chelates, anticoagulation reversal run in parallel rather than as a delay, and field-clearing erythromycin before endoscopy. It closes on the two recognition stems the boards reward, the herald bleed of an aortoenteric fistula and the two arteries where failed hemostasis sends you to interventional radiology.

Episode two moves below the ligament of Treitz and then to the mesenteric vessels, carrying the same rule forward: pick the imaging that feeds the next intervention and recognize the pattern that flips the algorithm. Acute lower GI bleeding branches on hemodynamic stability, CT angiography for the unstable patient because it hands interventional radiology the anatomy and colonoscopy at twelve to twenty-four hours for the stable one, with the etiologies read by pattern. Colon ischemia separates from diverticular bleeding on pain before bleeding, and isolated right colon ischemia flips the workup toward mesenteric imaging. Acute mesenteric ischemia turns on recognizing pain out of proportion to exam and reaching for CT angiography before lactate rises, then matching intervention to each of four etiologies.

Episode three works two mechanical emergencies that each hand you a recognition cue and a defined intervention with a clock embedded in it. For foreign bodies the urgency of removal follows the mechanism of injury, not the politeness of the object, sorting into three timing tiers from two-hour disc batteries to blunt objects that never come out. The food bolus doubles as the eosinophilic esophagitis biopsy opportunity that closes if you do not take it at the same procedure. For caustic ingestion, substance category drives the injury pattern, the airway is the first priority, and the Zargar grade at endoscopy drives short-term feeding and monitoring while late stricture and squamous cell carcinoma risk drive long-term surveillance.

Episode four closes the chapter with two emergencies that run on the same cue-plus-threshold-plus-intervention shape, where the threshold is a mechanism in disguise. For esophageal perforation the clock starts when the wall tears, and the twenty-four hour window separates clean primary closure from sealed stent and drainage because the mediastinal tissue planes change from friend to enemy. For acute colonic pseudo-obstruction the clock starts when the colon stops moving, and a four-step algorithm anchored by a cecal-diameter threshold and a neostigmine-with-cardiac-monitoring decision moves the patient from the conservative bundle to pharmacology to decompression to surgery. Laplace's law explains why the cecum fails first and the neostigmine contraindication list explains why every dose comes with atropine at the bedside.

Episode one of the GI Nutrition chapter builds the inpatient nutrition framework and the enteral access decisions. The organizing idea is that the labs lie and the instinct to feed faster is usually wrong. Refeeding syndrome is what happens when a starvation-adapted patient meets a carbohydrate load, so the active intervention is restraint with thiamine before glucose. Hospital malnutrition is not what a low albumin says it is, so GLIM separates the phenotypic deficit from the etiologic cause. And the route of nutrition follows the gut's functional state, with a functional gut winning every time.

Episode two takes the patient whose gut cannot do the work. Parenteral nutrition is a tool for a non-functional gut, with composition rules that follow from chemistry rather than biology and indication discipline that follows from trial data. Its long-term complications are driven by the loss of enteral stimulation, from gallbladder stasis and IFALD to manganese parkinsonism and catheter biofilm infection. Short bowel syndrome then turns on residual anatomy, where the colon's presence or absence determines both the rehabilitation trajectory and the complication pattern, and teduglutide's trophic effect explains both its efficacy and its surveillance burden.

Episode three reads the vitamins the way the boards test them, where every micronutrient produces a stereotyped phenotype that is the recognition cue on a stem. Behind each cue is a biochemical mechanism, and the same mechanism predicts the at-risk population and the replacement strategy. Memorizing the symptom list is the wrong frame; learning the mechanism lets the phenotype, the population, and the treatment fall out of it. The fat-soluble vitamins share a bile-salt absorption requirement, and the water-soluble vitamins carry the acute decisions, thiamine before glucose and B12 before folate.

Episode four closes the chapter with the minerals and trace elements, which run on the same logic as the vitamins: each element has a specific biochemical role and a specific exposure or pathology context that produces its phenotype. The boards favor the pairs that turn on a single mechanism, zinc inducing metallothionein to trap copper, cholestasis blocking biliary manganese excretion, and Brazil nuts concentrating selenium. Each element pairs a recognition cue with a population and a replacement strategy, the same teaching unit used for the vitamins.

Episode one of the GI Infections chapter builds C. diff around two competing problems: the defaults moved off metronidazole and vancomycin, and asymptomatic colonization is common enough that the wrong test drives unnecessary treatment. The organizing idea is that diagnosis exists to separate active disease from colonization, while treatment exists to get the right drug to the colonic lumen at the right concentration for the right duration. Severity thresholds decide treatment intensity, and fulminant features bring surgery into the conversation at presentation rather than after medical failure. Everything reduces to those two problems.

Recurrence is the dominant management problem in C. diff, and this episode organizes the entire toolkit around a single mechanism: the spore. Surviving spores germinate once the antibiotic stops, so every tool either keeps colonic drug above the killing threshold across successive germination waves or restores the commensal community that denies spores a niche. The drug you reach for depends on what was used first, the structural taper-and-pulse pattern matters more than the molecule, and after two or more recurrences the strategy shifts from antibiotics to microbiome restoration. Bezlotoxumab and prophylaxis close the loop in the right patients.

The community-acquired diarrheas separate cleanly once you group by acquisition pattern rather than symptoms, because the exposure history predicts the pathogen and the pathogen predicts the treatment. Travelers' diarrhea selects the empiric antibiotic by region and resistance, while rifaximin stays in the noninvasive niche because it is non-absorbed. Shiga-toxin-producing E. coli flips the rule entirely, since antibiotics release more toxin and loperamide prolongs exposure. Nontyphoidal Salmonella, Shigella, Yersinia, Vibrio, and Listeria each run on their own biology, and the foodborne toxin syndromes are recognized by time to onset that tells you cultures and antibiotics are unnecessary.

The parasitic diarrheas sort by exposure history, so the workup follows the suspected pathogen rather than a generic ova-and-parasite exam. Giardia comes from untreated water with a single-dose tinidazole answer, Entamoeba histolytica from endemic travel with two-stage tissue-then-luminal therapy, and Strongyloides is the pre-steroid serology question that prevents seventy-percent-mortality hyperinfection. Anisakis is the raw-fish larva cured by endoscopic removal. On the viral side, norovirus dominates on infectious dose and environmental persistence, which is why soap-and-water and bleach are the outbreak answers, while rotavirus fades under vaccination.

The immunocompromised gut expands the pathogen list, and the organizing move is that each organism lives behind a specific cue that names the therapy: name the host, the stain, and the histology, and you name the drug. CMV gives the owl-eye inclusion at the ulcer base treated with ganciclovir, with foscarnet as salvage when UL97 mutations break the prodrug pathway. MAC gives the PAS-positive, acid-fast-positive macrophage treated with a macrolide plus ethambutol, microsporidia turn on beta-tubulin pharmacology, and the coccidians answer to trimethoprim-sulfamethoxazole. The unifying thread is that antimicrobials hold the line while immune reconstitution provides durable clearance.

Episode one of the GI in the Immunocompromised Host chapter starts with a single recognition move: a transplant recipient on calcineurin inhibitor plus mycophenolate plus prednisone with diarrhea could be any of five entities at once, and time since transplant is the variable that reorders the differential. The first month belongs to the surgeon, the one-to-twelve-month window belongs to opportunistic infection, and beyond a year belongs to cumulative toxicity and malignancy. From there the reasoning runs on enzymes: donor-recipient serostatus and UL97 versus UL54 for CMV resistance, CYP3A4 for the calcineurin inhibitor trap, and dose-dependent crypt exposure for mycophenolate enteropathy. Sitting over all of it, Epstein-Barr virus drives the post-transplant lymphoproliferative disorder that responds first to reducing the immunosuppression that allowed it.

Episode two takes the other host state hiding behind the word transplant: the hematopoietic cell transplant recipient whose donor immune system attacks the host. The post-transplant timeline organizes everything, with the first twenty-one days belonging to conditioning toxicity rather than graft-versus-host disease, so the timeline decides which diagnosis is even allowed. Gut disease is staged by daily stool volume on the Glucksberg-Seattle thresholds, the histology anchors on crypt apoptosis, and the biopsy-bench differential always includes CMV because apoptosis is not pathognomonic. Treatment is methylprednisolone first and ruxolitinib second on the strength of a randomized trial, and the shared move across both host states is to pair every immunosuppression escalation with an infectious workup.

Episode three covers the non-transplant immunocompromised GI host, where two settings that look unrelated share one logic: identify the host state, and the host state opens a tiered differential. In HIV that state is the CD4 count, which converts a long pathogen list into strata that drive workup and surfaces the pre-antiretroviral-era entities still seen in late presenters, AIDS cholangiopathy, gut Kaposi sarcoma, and post-treatment IRIS. In chemotherapy-related neutropenia that state is the absolute neutrophil count, which defines typhlitis as a cecum-predominant enterocolitis managed conservatively with bowel rest and broad-spectrum antibiotics. The recurring move is that the number tells you what to look for and the entity tells you what to do, from antiretroviral therapy as the dominant intervention to the narrow list of surgical indications.

Episode four closes the module on checkpoint inhibitor toxicity, one entity with many organ targets, where releasing the brakes on T cells means the same cells recognize self. Drug class predicts the toxicity rate, with anti-CTLA-4 broad and severe, anti-PD-1 focal and milder, and combination highest, while grade drives therapy through a universal seventy-two-hour escalation window. The colitis algorithm runs grade-based steroids then infliximab or vedolizumab, with the choice turning on hepatic comorbidity and CMV risk. The single most tested distinction is that steroid-refractory hepatitis goes to mycophenolate mofetil, not infliximab, because infliximab is contraindicated by its own hepatotoxicity, and the whole framework extends to pneumonitis, endocrinopathies, and the other immune-related adverse events.

Episode one of the GI in Pregnancy chapter sets the physiologic baseline that every later stem depends on. The organizing idea is that pregnancy shifts a predictable set of labs, so any deviation pregnancy does not itself cause is by definition pathologic. From there it walks the volume, CBC, and liver-test changes, the fetal-protective imaging menu, and the antiemetic sequence for nausea and hyperemesis. The through-line is that you interpret a pregnant patient against a moved reference range, and you treat vomiting on a mechanistic ladder that ends with an absolute safety rule.

Episode two takes the upper-GI symptom that rides on the same pregnancy physiology as hyperemesis. GERD dominates because progesterone loosens the lower esophageal sphincter while estrogen strengthens the gastric mucosal barrier, so ulcers stay uncommon. The management is a stepwise sequence built on local-then-systemic safety logic, and the reasoning is that the rules fall out of mechanism rather than memorization. The one hard contraindication anchors the section: misoprostol is off the table because the same prostaglandin effect that heals ulcers induces labor.

Episode three covers the liver diseases that exist only because pregnancy is occurring, the syndromes for which delivery is the definitive treatment. It opens on intrahepatic cholestasis, where a stillbirth-risk curve inflecting at bile acids of one hundred drives delivery timing and a normal GGT separates it from obstruction. It then works through the preeclampsia, HELLP, and AFLP spectrum, teaching the distinction as a mechanism problem: vascular fibrin-and-shear versus fetal LCHAD-driven mitochondrial overwhelm. It closes on hepatic capsular rupture, the catastrophic complication that hemodynamic status triages.

Episode four takes the hepatic disease that is not caused by pregnancy but is reshaped by it. Viral hepatitis turns on virus-specific decisions: the tenofovir-plus-HBIG-and-vaccine stack that decisively cuts HBV vertical transmission, universal HCV screening with treatment deferred, genotype-driven HEV severity, and the empiric acyclovir that any pregnant patient with high transaminases and low bilirubin earns before HSV PCR returns. The pre-existing diseases follow an immune and pharmacokinetic principle: continue what is working and swap out the teratogens, with the specifics being mycophenolate out, azathioprine acceptable, trientine over penicillamine, and propranolol not nadolol.

Episode five flips a deeply intuitive instinct: pregnancy is not the time to back off immunosuppression, because the measured danger to the fetus is active maternal disease, not active maternal medicine. Once that principle is in place the medication rules become predictable, anything that maintained remission is continued and a small set of mechanism-toxic drugs is held. The molecular centerpiece is FcRn-mediated placental transfer, which loads IgG anti-TNF into cord blood by term but spares the Fab-fragment certolizumab, and that fact drives dose timing near term and infant vaccine decisions.

Episode six closes the chapter on two luminal problems governed by anatomy and timing. Post-bariatric pregnancy reads every rule off what the surgery changed: bypassed duodenum drops iron and calcium, reduced parietal cell exposure drops B12, the bypassed pylorus invalidates the OGTT, and mesenteric defects plus a gravid uterus produce internal hernia, so right upper quadrant pain after gastric bypass is internal hernia until proven otherwise. Cholelithiasis is governed by the trimester window: conservative when mild, second-trimester laparoscopic cholecystectomy when complicated, and ERCP built around keeping fetal dose under one milligray.

Episode one of the Hereditary GI Cancer Syndromes chapter builds the diagnostic framework the rest of the series depends on. The organizing idea: universal tumor testing catches the carriers that pedigree gatekeeping misses, because family history alone overlooks thirty to fifty percent of them. The four-protein immunohistochemistry pattern then decides the next move, with combined MLH1 and PMS2 loss running a sporadic-cancer rule-out before germline sequencing and everything else reflexing straight to the blood test. The through-line is that protein-loss pattern drives testing, and once a proband is confirmed, cascade testing of relatives becomes the highest-yield step.

Episode two takes Lynch syndrome, the syndrome the diagnostic framework most often surfaces, and anchors everything to one idea: lifetime cancer risk varies sharply by gene, and that gene-specific risk sets each surveillance interval to the dwell time of preinvasive disease in that organ. MLH1 and MSH2 carriers drive high colorectal and endometrial risk, while MSH6 flips uterine cancer above colorectal and MSH2 concentrates the upper urothelial risk. The reasoning extends to why the colonoscopy interval is short, why the cancer operation is extended, why endometrial surveillance is a bridge to hysterectomy, and why aspirin and pembrolizumab both trace back to the mutational burden the syndrome generates.

Episode three works the adenomatous polyposis syndromes by their governing logic: if you know the gene, you know the polyp count, the polyp type, and the surgery. APC drives classic FAP toward near-certain colorectal cancer by forty, the same gene at its ends produces the softer attenuated phenotype, and biallelic MUTYH mimics attenuated FAP through an autosomal recessive pattern of affected siblings and unaffected parents. The surgical pivot is not whether to take the colon but whether to take the rectum, which decides itself on polyp burden. After the colon is gone the duodenum becomes the surveillance organ, with Spigelman staging turning ampullary adenomas into an EGD interval and a pancreaticoduodenectomy conversation.

Episode four moves from adenoma to hamartoma, where the dominant risk shifts away from colorectal cancer. STK11 drives Peutz-Jeghers, and the resection threshold is calibrated to intussusception rather than cancer, so any small bowel polyp over one centimeter comes out. PTEN drives Cowden, where the cancer burden tracks baseline PI3K signaling into breast and thyroid and the GI role is recognition through mixed-histology polyposis. CDH1 flips the algorithm hardest: multifocal submucosal signet-ring disease beneath intact mucosa makes endoscopy unreliable, so prophylactic total gastrectomy between twenty and thirty is the standard of care. The thread is constant, the gene dictates the histology, the histology dictates the natural history, and the natural history dictates whether the answer is surveillance, polyp-by-polyp resection, or removal of the organ.

Episode five closes the chapter with hereditary pancreatic cancer and the family-systems coordination that binds every syndrome together. The gating principle is absolute lifetime risk, not relative risk: surveillance begins above roughly five percent, so STK11, CDKN2A, PRSS1, and familial kindreds qualify on genotype alone while BRCA1, BRCA2, ATM, PALB2, and Lynch enter only with a family-history driver. The treatment side ties platinum and PARP inhibitors back to synthetic lethality in homologous-recombination-deficient tumors. The coordination side names the real failure mode, the carrier whose colonoscopy stays on schedule while gynecologic or urologic surveillance lapses, and the board traps around cascade testing, the GINA insurance gap, and the non-actionable variant of uncertain significance.